Today: 9 June 2026
Berkshire Pushes Macy’s, Inc. Stock—What’s Next for Traders Before Monday
16 May 2026
2 mins read

Berkshire Pushes Macy’s, Inc. Stock—What’s Next for Traders Before Monday

New York, May 16, 2026, 09:05 EDT

Macy’s, Inc. shares will start the next U.S. session coming off a boost from Berkshire Hathaway. The conglomerate revealed a new position in the department store name late Friday. The stock finished normal trading at $18.41, up 0.55%. The New York Stock Exchange closed for the weekend.

That’s important with the regular-session tape still looking soft. Macy’s dropped roughly 5.5% on the week off its May 8 close at $19.48, losing 4.1% on Monday before clawing back a bit with a minor rebound Friday.

Berkshire’s latest filing pushed traders to take another look at the stock. The Form 13F, required every quarter, landed May 15 and showed Berkshire held 3,038,355 Macy’s shares as of March 31, worth close to $55 million. The disclosure included two separate Macy’s positions.

Berkshire’s Macy’s stake is minor, but the stock jumped 6.3% after hours on the news, Reuters said. Berkshire also reported boosting its Delta Air Lines holding and made other portfolio moves following Greg Abel’s takeover as CEO from Warren Buffett.

Macy’s is pushing its plan to focus on fewer, better stores while putting more cash behind stronger stores, Bloomingdale’s and Bluemercury. The company needs investors on board. In March, Macy’s reported fourth-quarter comparable sales up 1.8%. Bloomingdale’s same-store sales rose 9.9%. Comparable sales include established stores and online, excluding new store openings and closures.

Macy’s cut its guidance for fiscal 2026. The company now sees net sales between $21.4 billion and $21.65 billion, which is lower than the $21.8 billion Macy’s expects in fiscal 2025. Management pegged comparable sales growth between down 0.5% and up 0.5%. Adjusted diluted EPS is forecast at $1.90 to $2.10, also down from $2.15 for fiscal 2025.

Macy’s CEO Tony Spring is cautious. In March, he told the Associated Press, “there’s more unknown than there is known,” and added the company needs to “lean into what we can control.” KSAT

Mixed picture for competitors. Bloomingdale’s picked up share in the fourth quarter while Saks Global handled bankruptcy, according to Retail Dive. Macy’s luxury brand got that boost, but the department-store and discretionary retail market is still tough.

Macy’s still faces risks going into Monday. A Berkshire stake won’t fix slow mall traffic, tariffs, consumer caution or too many promotions. Dana Telsey at Telsey Advisory Group said in a note that “rightsizing the store base should improve long-term profitability,” but macro pressures, tariffs and soft traffic keep near-term sales and profit growth capped. Dallas News

Other big retailers aren’t sounding bullish. In March, Reuters said Walmart and Kohl’s were both cautious with their guidance. Analysts at Telsey warned about macro pressure, soft traffic, tariff uncertainty, and heavier promotions putting pressure on results in the near term.

Premarket volume needs a look before the next session, as traders watch if Berkshire news is enough to hold buyers past the open. Also keep an eye on SPDR S&P Retail ETF—a retail ETF that dropped to $79.09 from $80.38 on Friday.

Macy’s is set for a stronger start Monday unless the broader market falls. But the real level to watch isn’t just the open. If shares get back above and hold Friday’s close around $19.48, the Berkshire move may start to unwind recent losses. Failure to hold that spot and the bounce risks looking like a headline-driven pop instead of a shift in trend.

Stock Market Today

  • Constant and Constant Advises Piraeus Bank on Safe Bulkers Euronext Athens Dual Listing
    June 9, 2026, 9:51 AM EDT. Constant and Constant Greece and UK firm TLT advised Piraeus Bank on the dual listing of Safe Bulkers, Inc. on Euronext Athens, marking the first Greek shipping company listed in New York to also trade on Athens' exchange. Safe Bulkers, a marine dry bulk carrier with 45 vessels, is now accessible to both U.S. and Greek investors. The legal teams led cross-border due diligence covering loan facilities, guarantees, and fleet agreements to ensure compliance. This move is expected to pave the way for similar listings, enhancing Greece's capital markets. Safe Bulkers' CFO praised the firms for precise, detailed legal support throughout the complex process.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Markets Drop Fed Rate Cut Bets for 2026
Previous Story

Markets Drop Fed Rate Cut Bets for 2026

UiPath shares up 6% ahead of earnings, traders look for what moves PATH next
Next Story

UiPath shares up 6% ahead of earnings, traders look for what moves PATH next

Go toTop